(Q37892341)

24 August 2017

1 reference

title

Novel strategies for the treatment of small-cell lung carcinoma (English)

1 reference

24 August 2017

William N William

1

1 reference

24 August 2017

Bonnie S Glisson

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

21 June 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

611-619

1 reference

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Prophylactic cranial irradiation in extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

ZD0473 treatment in lung cancer: an overview of the clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Identification of novel regions of altered DNA copy number in small cell lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A small-cell lung cancer genome with complex signatures of tobacco exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Cigarette smoking and cancer risk: modeling total exposure and intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Integrated classification of lung tumors and cell lines by expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Differentially expressed microRNAs in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Small cell lung carcinoma (SCLC): the angiogenic phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Chromosomal abnormalities in a primary small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Small-Cell Carcinoma of Lung: Reinduction Therapy After Late Relapse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Reinduction chemotherapy in small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Cytogenetic studies in 11 patients with small cell carcinoma of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Comparative proteomics of pulmonary tumors with neuroendocrine differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.90

Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization

31 March 2020

1 reference

12 December 2020

Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).

1 reference

12 December 2020

Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer.

1 reference

12 December 2020

Chromosome alterations in human small cell lung cancer: frequent involvement of 5q

1 reference

12 December 2020

Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin

1 reference

12 December 2020

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

1 reference

12 December 2020

Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors

1 reference

12 December 2020

First-line chemotherapy rechallenge after relapse in small cell lung cancer

1 reference

12 December 2020

Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles

1 reference

12 December 2020

Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung

1 reference

12 December 2020

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions

1 reference

12 December 2020

Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.

1 reference

12 December 2020

Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines

1 reference

12 December 2020

10.1038/NRCLINONC.2011.90

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1032251011

0 references

1 reference